Login to Your Account



Ofatumumab Misses NHL Mark; Genmab Shares Take a Tumble

By Cormac Sheridan


Wednesday, August 19, 2009
Shares in Genmab A/S dropped sharply Tuesday on news that its anti-CD20 antibody ofatumumab failed to demonstrate a significant objective response rate in non-Hodgkins lymphoma (NHL) patients who were refractory to other treatments. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription